CD4 and AIDS: We examine the impact of changing the eligibility criterion for antiretroviral therapy from CD4 count <200 to CD4 count <350 on the number of person-years on ART, the number of AIDS deaths averted, and the costs of the change including the costs of additional tests and recruitment costs.